Aclarion, Inc. (ACON)
| Previous Close | 0.9293 |
| Open | 0.9200 |
| Bid | 0.8901 x 1000 |
| Ask | 0.9900 x 800 |
| Day's Range | 0.8600 - 0.9298 |
| 52 Week Range | 0.7830 - 4.0500 |
| Volume | |
| Avg. Volume | 1,329,532 |
| Market Cap | 7.196M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.1200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two YearsTwo Year Results and the Schedule of Future Clinical Trials to be Outlined at the Annual State of Spine Surgery Think Tank 2022SAN MATEO, CA / ACCESSWIRE / June 22, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary algorithms to identify the location of chronic low back pain, announced today that the Company will
- ACCESSWIRE
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering
SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the closing of its previously announced initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 share
- ACCESSWIRE
Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering
SAN MATEO, CA / ACCESSWIRE / April 21, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the pricing of its initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 shares of common stock.
